Cargando…

Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms

BACKGROUND: Pelvic lymph node dissection (PLND) is recommended method for detecting prostate cancer (PCa) nodal metastases although associated with serious complications. In this study, we aimed to assess benefit/harm of routine PLND in intermediate risk PCa patients and to compare diagnostic yield...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodeta, Branimir, Baric, Hrvoje, Hatz, Dominik, Jozipovic, Danijel, Augustin, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657577/
https://www.ncbi.nlm.nih.gov/pubmed/37980520
http://dx.doi.org/10.1186/s12894-023-01362-y
_version_ 1785148178121621504
author Lodeta, Branimir
Baric, Hrvoje
Hatz, Dominik
Jozipovic, Danijel
Augustin, Herbert
author_facet Lodeta, Branimir
Baric, Hrvoje
Hatz, Dominik
Jozipovic, Danijel
Augustin, Herbert
author_sort Lodeta, Branimir
collection PubMed
description BACKGROUND: Pelvic lymph node dissection (PLND) is recommended method for detecting prostate cancer (PCa) nodal metastases although associated with serious complications. In this study, we aimed to assess benefit/harm of routine PLND in intermediate risk PCa patients and to compare diagnostic yield of five different nomograms in predicting lymph node invasion (LNI). METHODS: Retrospective analysis of consecutive PCa patients with intermediate risk of biochemical recurrence who underwent open radical prostatectomy (RP) with bilateral PLND between January 2017 and December 2019 at our institution. Partin, 2012-Briganti, 2018-Briganti, Cagiannos and Memorial Sloan Kettering Cancer Center (MSKCC) values were calculated. To compare accuracy, sensitivity, specificity, and area under receiver-operating curve (AUC) were calculated and then optimal cutoff values were estimated, analyses repeated and compared. To assess benefit and harm of PLND, relative risk (RR) and number need to treat (NNT) with LNI and complications set as outcome were calculated. RESULTS: Total 309 subjects. Average age 62.2 years, average PSA 7.2 ng/mL; 18 (5.8%) had LNI; 88 (28.5%) suffered Clavien-Dindo grade 3–5 complication. AUC for predicting LNI: 0.729 for 2012-Briganti, 0.660 for MSKCC, 0.521 for 2018-Briganti, 0.486 for Cagiannos, and 0.424 for Partin. None of pairwise AUC comparisons based on default and newly established cutoff values were statistically significant. Lowest NNT was for Partin and Cagiannos with default cutoff (≥ 5%). Risks of serious complications between higher/lower than cutoff values were non-significant across nomograms. CONCLUSIONS: 2012-Briganti nomogram outperforms, although not significantly, MSKCC, 2018-Briganti, Cagiannos, and Partin nomograms in classifying LNI in intermediate risk PCa patients. Routine PLND in these patients should be avoided, due to high rate and severity of complications.
format Online
Article
Text
id pubmed-10657577
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106575772023-11-18 Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms Lodeta, Branimir Baric, Hrvoje Hatz, Dominik Jozipovic, Danijel Augustin, Herbert BMC Urol Research BACKGROUND: Pelvic lymph node dissection (PLND) is recommended method for detecting prostate cancer (PCa) nodal metastases although associated with serious complications. In this study, we aimed to assess benefit/harm of routine PLND in intermediate risk PCa patients and to compare diagnostic yield of five different nomograms in predicting lymph node invasion (LNI). METHODS: Retrospective analysis of consecutive PCa patients with intermediate risk of biochemical recurrence who underwent open radical prostatectomy (RP) with bilateral PLND between January 2017 and December 2019 at our institution. Partin, 2012-Briganti, 2018-Briganti, Cagiannos and Memorial Sloan Kettering Cancer Center (MSKCC) values were calculated. To compare accuracy, sensitivity, specificity, and area under receiver-operating curve (AUC) were calculated and then optimal cutoff values were estimated, analyses repeated and compared. To assess benefit and harm of PLND, relative risk (RR) and number need to treat (NNT) with LNI and complications set as outcome were calculated. RESULTS: Total 309 subjects. Average age 62.2 years, average PSA 7.2 ng/mL; 18 (5.8%) had LNI; 88 (28.5%) suffered Clavien-Dindo grade 3–5 complication. AUC for predicting LNI: 0.729 for 2012-Briganti, 0.660 for MSKCC, 0.521 for 2018-Briganti, 0.486 for Cagiannos, and 0.424 for Partin. None of pairwise AUC comparisons based on default and newly established cutoff values were statistically significant. Lowest NNT was for Partin and Cagiannos with default cutoff (≥ 5%). Risks of serious complications between higher/lower than cutoff values were non-significant across nomograms. CONCLUSIONS: 2012-Briganti nomogram outperforms, although not significantly, MSKCC, 2018-Briganti, Cagiannos, and Partin nomograms in classifying LNI in intermediate risk PCa patients. Routine PLND in these patients should be avoided, due to high rate and severity of complications. BioMed Central 2023-11-18 /pmc/articles/PMC10657577/ /pubmed/37980520 http://dx.doi.org/10.1186/s12894-023-01362-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lodeta, Branimir
Baric, Hrvoje
Hatz, Dominik
Jozipovic, Danijel
Augustin, Herbert
Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
title Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
title_full Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
title_fullStr Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
title_full_unstemmed Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
title_short Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
title_sort benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657577/
https://www.ncbi.nlm.nih.gov/pubmed/37980520
http://dx.doi.org/10.1186/s12894-023-01362-y
work_keys_str_mv AT lodetabranimir benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms
AT barichrvoje benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms
AT hatzdominik benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms
AT jozipovicdanijel benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms
AT augustinherbert benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms